Drugs for Urinary Frequency, Enuresis and Incontinence

NHSL Medicines Guidance
NHS Lanarkshire

Antimuscarinics (Urinary)

Preferred list (P)

SOLIFENACIN

 

Total list (T)

OXYBUTYNIN 

TOLTERODINE

TROSPIUM CHLORIDE (Regurin XL® capsules)

Prescribing notes:

The need for continuing antimuscarinic drug therapy should be reviewed every 4-6 weeks until symptoms stabilise, and then every 6-12 months.

Beta3-Adrenoceptor Agonists

Total list (T)

MIRABEGRON

  • Mirabegron is contraindicated in patients with severe uncontrolled hypertension (systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg, or both).
  • Blood pressure should be measured before starting treatment and monitored regularly during treatment, especially in patients with hypertension. MHRA Drug Safety Update vol 9 issue 3 October 2015: 1.

VIBEGRON

Prescribing notes:

  • Beta3-Adrenoceptor Agonists are only recommended for patients in whom antimuscarinic drugs are ineffective, contraindicated, or not tolerated.
  • Efficacy should be assessed after three months of treatment. Treatment with mirabegron or vibegron should only continue as long-term therapy if clinical benefit is established during this period. 

Primary Nocturnal Enuresis

Preferred list (P)

DESMOPRESSIN 200mcg tablets

 

Stress Urinary Incontinence (SUI) in Women

Preferred list (P)

PELVIC FLOOR EXERCISES

NHSL Joint Adult Formulary Key

To indicate the category of a formulary medicine, updated sections adopt the following key:

Preferred list (P): First-line formulary choices.

Total list (T): Alternative choices when preferred list options not effective/not tolerated, or not indicated.

Specialist initiation (S1): Specialist initiation, or on the advice of a Consultant or Specialist Practitioner in this therapeutic area. Continuation in primary care is acceptable.

Specialist use only (S2): Supply via hospital, Homecare Service or a hospital based prescription (HBP) for dispensing by community pharmacy. Not prescribed in primary care setting.

Editorial Information

Last reviewed: 31/01/2022

Next review date: 30/06/2026

Author(s): NHSL.

Version: Please refer to the introduction section for an explanation of the review dates above.

Approved By: ADTC

Reviewer name(s): ADTC.